The UK government is giving an “ethical signal” to study the effects of COVID-19 re-infection on the immune system

As many as 64 healthy young people between the ages of 18 and 30 who had previously contracted COVID-19 and were completely cured will now be recruited to participate in a new ‘human challenge test’ to study how the body’s immune system responds to COVID. -19 virus.

Significantly, Oxford researchers have obtained ethical approval for this trial, which hopes to test the immune response needed to protect people from re-infection.

The aim of the study is to provide a better understanding of the virus and to provide more accurate information with new tests. The Oxford trial for human challenges will reinfect participants who were previously naturally exposed to the virus, but this time in a safe and controlled environment for research purposes. Respondents will be paid £ 5,000 and will be quarantined for 17 days in hospital.

Ethical nodding to judge a human challenge?

The test will focus on what kind of immune response can stop people from becoming infected again, and it will also try to assess how both the virus and the immune system react a second time.

Talking to local media in the UK about what to expect from the challenge study, Helen McShane, a professor of vaccinology at Oxford University’s Department of Pediatrics and lead researcher in the study, noted that the study will teach researchers things other studies can’t because unlike of cases of natural infection, the re-infection process will take place in tight laboratory conditions and scientists will know exactly how their immune system reacted to the first COVID-19 infection, with more annoying details about when exactly the infection occurs and how many viruses each contracted and why the professor said.

Trial human challenges

The study is said to take place in two phases with different participants in each phase. The first phase, which begins by the end of April 2021, is expected to establish the lowest dose of the virus, in approximately 50 percent of participants who were previously naturally infected, can be caught and begin to replicate, but remain asymptomatic or produce little asymptomatic.

However, the second phase is expected to begin later this year, where all participants will be infected with the standardized dose of virus applied in the first phase. After that, the meticulous process of data collection and analysis will begin with a careful definition of the underlying immune response in volunteers.

What is important to note is that the virus used in the first study will be the original strain from Wuhan in China.

Subjects will be quarantined in a specially designed hospital package for at least 17 days under the strict supervision of a research team. He will then undergo a number of medical tests, including CT scans of the lungs, MRI scans and other necessary formalities to perform the test.

Respondents who are engaged on a voluntary basis will be fired only after they recover and are no longer at risk of infecting others. The full duration of the study will be 12 months, including at least eight follow-up examinations after discharge.

What is a challenging trial?

The professor explained that examining the human challenge in terms of medical research is a carefully substantiated study involving intentionally infecting subjects with a pathogen or beetle, to study the effects of that infection to better understand the infection to be able to develop a viable cure.

The professor noted that there are still many doubts about the virus and its long-term effects on the human body, and studies like this can allow scientists to improve their understanding by collecting high-quality data on the immune system and responses.